French pharmaceutical giant Sanofi has agreed to acquire U.S. biotech Dynavax Technologies in a deal valued at about $2.2 billion in cash. The all-cash transaction is poised to expand Sanofi’s position in adult immunization by adding a marketed hepatitis B vaccine and a promising shingles vaccine candidate to its global vaccine portfolio.
Under the acquisition agreement, Sanofi will launch a cash tender offer to buy all outstanding shares of Dynavax at $15.50 per share, representing a roughly 39% premium over the company’s recent closing price. The transaction, unanimously approved by Dynavax’s board, is subject to customary closing conditions and expected to conclude in the first quarter of 2026.
Dynavax’s flagship product, HEPLISAV-B, is an adult hepatitis B vaccine already approved in the United States. What sets it apart from other hepatitis B vaccines is its two-dose schedule over a single month, offering faster protection compared with traditional vaccines that require multiple doses over several months. Peak U.S. sales are forecast to reach meaningful levels, making it an attractive addition to Sanofi’s lineup.
In addition to HEPLISAV-B, Sanofi will gain control of Dynavax’s experimental shingles vaccine candidate, Z-1018, currently in Phase 1/2 clinical development. Early data suggest that Z-1018 produces a strong immune response and may have a favorable safety profile, positioning it as a potential competitor to established products like GSK’s Shingrix if later-stage trials succeed.
Sanofi’s move comes as part of a broader strategy to diversify and strengthen its vaccine business amid shifting industry dynamics. The company already has a substantial immunization portfolio, including shots for influenza, polio and the respiratory syncytial virus (RSV). Adding Dynavax’s assets enhances Sanofi’s presence across the adult vaccine market, particularly in areas with significant unmet need.
The acquisition follows a period of pipeline challenges for Sanofi. Earlier setbacks in the year included regulatory disappointments for some clinical programs, underscoring the importance of strategic deals to replenish growth engines. Industry analysts view the Dynavax deal as a logical fit, given the complementarity of the vaccines and Sanofi’s existing capabilities in vaccine development and commercialization.
From Dynavax’s perspective, the merger offers the company’s products and pipeline broader commercial reach and development support through Sanofi’s global infrastructure. The acquisition could accelerate access to Dynavax’s vaccines in new markets and strengthen efforts to address key public health challenges.
Adult immunization remains a priority for public health authorities, with many adults lacking protection against diseases like hepatitis B and shingles. In the United States alone, tens of millions of adults born before the early 1990s are unvaccinated against hepatitis B, leaving them at risk for serious liver disease, cirrhosis and cancer. Shingles, caused by the varicella-zoster virus, affects a substantial portion of the adult population, often causing painful rashes and, in severe cases, long-term nerve pain.
The deal does not affect Sanofi’s 2025 financial guidance and will be funded from available cash resources. If the tender offer is successful and the merger completes, Dynavax will become a wholly-owned subsidiary of Sanofi. The combined company plans to leverage Sanofi’s commercial reach, regulatory experience and production scale to maximize the potential of Dynavax’s vaccines.
As the global vaccine landscape evolves, acquisitions like this reflect how major pharmaceutical firms are positioning themselves to meet both public health needs and competitive market pressures. For Sanofi, the Dynavax purchase represents a strategic investment in adult immunization that could offer long-term revenue opportunities and broaden its footprint in a key therapeutic area
